Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Assertio $70 million convertible senior notes offering
The 6.5% notes are due 2027
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
Oak Street Health $180.3 million secondary offering
We advised the joint book-running managers on the equity offering
Tenaya Therapeutics $75 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
ADC Therapeutics $175 million term loan facility and other financings
We advised the company on the new facility, a $115 million exchange and a $6.25 million share sale
Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
RxSight $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market